Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7) (MALS verified)

사용자 리뷰
제품 번호/규격
가격
수량
FUN-MY2097-100ug
$415.00
FUN-MY2097-1mg (500ug X 2)
$2735.00
ETA of in-stock products:2 business days
총 항목 수 제품 금액$ 0

제품 세부정보

  • Source

    Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7) is a recombinant chimeric monoclonal antibody expressed in HEK293, which combines the variable region of a mouse monoclonal antibody with human constant domain.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    1A7

  • Isotype

    Human IgG1, Kappa

  • Host Species

    Mouse

  • Reactivity

    Hendra virus

  • Immunogen

    Recombinan Hendra virus Pre-Fusion glycoprotein (A263T) is expressed from human HEK293 cells

  • Specificity

    Specifically recognizes Hendra virus Pre-Fusion glycoprotein (A263T).

  • Application

    Application
    Recommended Usage
    Western Blot
    10-5 ug/mL
    ELISA
    0.2-2 μg/mL
  • Purification

    Protein A purified / Protein G purified.

  • Aggregation

    Less than 10%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

  • Bioactivity-ELISA

     Fusion glycoprotein ELISA

    Immobilized Hendra virus Pre-Fusion glycoprotein (A263T), His Tag (Cat. No. FUN-H52H4) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7) (Cat. No. FUN-MY2097) with a linear range of 0.6-9.8 ng/mL (QC tested).

    Protocol
  • Western Blot

     Fusion glycoprotein WESTERN BLOT
  • Detection of Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7), Human IgG1 | Human Kappa, HEK by Western Blot. Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7), Human IgG1 | Human Kappa, HEK at 5ug/ml dilution + Hendra virus Pre-Fusion glycoprotein (A263T), His Tag at 400ng.
    Secondary Antibody: (HFC)-HRP Goat Anti-Human IgG,Fcγ fragment specific (min X Bov,Hrs,Ms Sr Prot) at 1/2000 dilution.
    Predicted band size: 65 kDa 12% Bis-Tris Protein Gel.

사용자 리뷰
댓글 남기기

배경 소개

Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

프론티어 진행

 
의약품 개발 진행
  • 영어 이름:

    Respiratory syncytial virus F protein

  • 카테고리:

  • 상장 의약품 수:

    3 상세

  • 임상 의약품 수:

    7 상세

  • 최고 개발 단계:

    Approved

연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
  • 배경
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호